Business
biOasis to Begin Trading on OTCQX® Marketplace in the U.S.
biOasis to Begin Trading on OTCQX® Marketplace in the U.S..
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n \n biOasis to Begin Trading on OTCQX® Marketplace in the U.S.\n \n \nbiOasis to Begin Trading on OTCQX® Marketplace in the U.S.\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb 24, 2014) - biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCQX:BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX® under the symbol BIOAF. \n \"Joining the OTCQX brings greater visibility and awareness of biOasis to the US and abroad investment communities,\" said Rob Hutchison, biOasis' Chairman & CEO. \"It comes at an opportune time when we are moving forward with initiatives to license our breakthrough drug delivery platform, Transcend, to major players in the pharmaceutical industry. Transcend has the potential to expand the application of a wide range of clinically approved and research therapeutics, and to potentially extend their patent life.\"\n About Transcend\n Transcend offers the creation of a new class of drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain metastatic cancer and other brain disorders, such as neurodegeneration and metabolic disease. The blood-brain barrier represents the single greatest challenge in treating diseases and other disorders within the brain. Diseases such as cancer are readily treated in many areas of the body, but drugs designed to treat cancer simply cannot penetrate the blood-brain barrier.\n Over the past five years, biOasis has developed a unique and novel blood-brain barrier vector called Transcend. Trials in animal models have shown that Transcend can deliver Herceptin®, a chemotherapeutic used to treat HER2-positive breast cancer, in sufficient quantity to the brain to significantly reduce the number of HER2-positive metastatic brain tumors. Further, after only four treatments, the remaining tumor masses were reduced in size by an average of 58%. \n Also in animal models, the company has demonstrated that the Transcend vector could deliver a 4-to-8-fold increase of a variety of different therapeutic biologics across the blood-brain-tumor barrier versus the compounds on their own. \n The ability to more effectively permeate both the blood-brain and the blood-tumor barrier ope...